The Fast Track FIT study: diagnostic accuracy of faecal immunochemical test for haemoglobin in patients with suspected colorectal cancer
Authors:
Open Access
- 1 April 2021
- journal article
- research article
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 71 (709) , e643-e651
Abstract
Background: The faecal immunochemical test (FIT) is now available to support clinicians in the assessment of patients at low risk of colorectal cancer (CRC) and within the bowel cancer screening programme.Aim: To determine the diagnostic accuracy of FIT for CRC and clinically significant disease in patients referred as they were judged by their GP to fulfil National Institute for Health and Care Excellence guideline 12 (NG12) criteria for suspected CRC.Design and setting: Patients referred from primary care with suspected CRC, meeting NG12 criteria, to 12 secondary care providers in Yorkshire and Humber were asked to complete a FIT before investigation.Method: The diagnostic accuracy of FIT based on final diagnosis was evaluated using receiver operating characteristics analysis. This permitted a statistically optimal cut-off value for FIT to be determined based on the maximisation of sensitivity and specificity. Clinicians and patients were blinded to the FIT results.Results: In total, 5040 patients were fully evaluated and CRC was detected in 151 (3.0%). An optimal cut-off value of 19 µg Hb/g faeces for CRC was determined, giving a sensitivity of 85.4% (95% confidence interval [CI] = 78.8% to 90.6%) and specificity of 85.2% (95% CI = 84.1% to 86.2%). The negative predictive value at this cut-off value was 99.5% (95% CI = 99.2% to 99.7%) and the positive predictive value 15.1% (95% CI = 12.8% to 17.7%). Sensitivity and specificity of FIT for CRC and significant premalignant polyps at this cut-off value were 62.9% (95% CI = 57.5% to 68.0%) and 86.4% (95% CI = 85.4% to 87.4%), respectively; and when including all organic enteric disease were 35.7% (95% CI = 32.9% to 38.5%) and 88.6% (95% CI = 87.5% to 89.6%), respectively.Conclusion: FIT used in patients fulfilling NG12 criteria should allow for a more personalised CRC risk assessment. FIT should permit effective, patient-centred decision-making to inform the need for, type, and timing of further investigation.Keywords
This publication has 39 references indexed in Scilit:
- Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn’s Disease PatientsDigestive Diseases and Sciences, 2016
- Evaluation of a faecal calprotectin care pathway for use in primary carePrimary Health Care Research & Development, 2016
- Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptomsClinical Chemistry and Laboratory Medicine (CCLM), 2016
- Impact of Preanalytical Factors on Fecal Immunochemical Tests: Need for New Strategies in Comparison of MethodsThe International Journal of Biological Markers, 2015
- Colorectal cancer screening—insights and challengesNature Reviews Gastroenterology & Hepatology, 2014
- Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteriaColorectal Disease, 2014
- Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screeningClinical Chemistry and Laboratory Medicine (CCLM), 2014
- Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trialThe Lancet, 2013
- Low faecal haemoglobin concentration potentially rules out significant colorectal diseaseColorectal Disease, 2012
- Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancerClinical Chemistry and Laboratory Medicine (CCLM), 2011